SCHEMBL5723901

SCHEMBL5723901

C#Cc1nc(N)nc2c1ncn2Cc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.60
ALDH1A1 P00352 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
HIF1A Q16665 1/20 0.60
PHLPP2 Q6ZVD8 1/20 0.60
ADORA2A P29274 8/20 0.57
ADORA1 P30542 3/20 0.57
HRH4 Q9H3N8 1/20 0.56
PNP P00491 1/20 0.53
PI4KA P42356 1/20 0.52
PI4K2B Q8TCG2 1/20 0.52
PI4K2A Q9BTU6 1/20 0.52
PI4KB Q9UBF8 1/20 0.52
PDE4A P27815 1/20 0.52
PDE4B Q07343 1/20 0.52
PDE4C Q08493 1/20 0.52
PDE4D Q08499 1/20 0.52
CDK1 P06493 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5723706 0.83 CYP1A2 (0.54) CYP1A2ALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL1640041 0.82 PDE4A (0.69) CYP1A2ALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL6272417 0.81 ALDH1A1 (0.66) CYP1A2ALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL5723726 0.80 CYP1A2 (0.53) CYP1A2ALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL5723947 0.80 CYP1A2 (0.53) CYP1A2ALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL30586356 0.80 CYP1A2 (0.64) CYP1A2ALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL30586350 0.80 CYP1A2 (0.64) CYP1A2ALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL5724169 0.80 CYP1A2 (0.64) CYP1A2ALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL27626391 0.79 CYP1A2 (0.52) CYP1A2ALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL25543494 0.78 ADORA2A (0.70) CYP1A2ALDH1A1CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1515970-B1 ALKYNYLPURINE COMPOUNDS AND PRODUCTION METHODS THEREOF SUMITOMO CHEMICAL CO (JP) 2006-10-18 EP disclosed
US-20060100429-A1 Alkynylpurine compounds and production methods thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-05-11 US disclosed
CN-1662536-A Alkynylpurine compounds and production methods thereof SUMITOMO CHEMICAL CO (JP) 2005-08-31 CN disclosed
EP-1515970-A1 ALKYNYLPURINE COMPOUNDS AND PRODUCTION METHODS THEREOF Sumitomo Chemical Company, Limited (JP) 2005-03-23 EP disclosed
WO-2003106458-A1 ALKYNYLPURINE COMPOUNDS AND PRODUCTION METHODS THEREOF SUMIKA FINE CHEMICALS CO., LTD. (JP) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100429-A1 Alkynylpurine compounds and production methods thereof TPMT, IMPDH1, IMPDH2 CYP1A2 327/4885ALDH1A1 57/4885CYP3A4 696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.